In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Indaptus Therapeutics (INDP – Research Report), with a price target of $12.00. The company’s shares closed yesterday at $1.85.
According to TipRanks, Selvaraju is an analyst with an average return of -6.9% and a 32.00% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Genmab, MoonLake Immunotherapeutics, and Anavex Life Sciences.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Indaptus Therapeutics with a $8.00 average price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $3.32 and a one-year low of $1.25. Currently, Indaptus Therapeutics has an average volume of 13.53K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Intec Pharma Ltd. is a clinical-stage biopharmaceutical company engaging in the development of drugs based on proprietary Accordion Pill platform technology. Its Accordion Pill technology is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs under development by utilizing an efficient gastric retention and specific release mechanism. The company was founded by Zvi Joseph in 2000 and is headquartered in Jerusalem, Israel.
Read More on INDP:
